Sciatica Treatment Market Analysis North America,Europe,Asia,Rest of World (ROW) - US,Canada,UK,Germany,China - Size and Forecast 2023-2027

Sciatica Treatment Market Forecast 2023-2027

The global sciatica treatment market size is estimated to grow by USD 3.09 billion at a CAGR of 4.83% between 2022 and 2027. The market experiences momentum from an increasing understanding of sciatica and the expanding occurrence of risk factors associated with the condition. Additionally, regulatory backing for pharmaceuticals in the pipeline contributes to market dynamics. Conversely, the absence of sanctioned treatments and the hazards linked to treatment, along with drug disappointments during clinical trials, impede market progress.

Sciatica is often confused with general back pain; it can cause pain in the lower back if the condition is left untreated for the long term. In order to raise awareness and avoid delays in diagnosis by means of certain programs, a number of government and non-governmental organizations are involved. For instance, OrthoInfo, the American Academy of Orthopaedic Surgeons (AAOS) patient education site, provides awareness about sciatica via articles, videos, and animations in the US. Similarly, myDr.com.au,  An Australian healthcare website provides complete and up-to-date information on the different health problems associated with sciatica. Furthermore, the Health Navigator website by the Health Navigator Charitable Trust provides free access to online health information related to sciatica in New Zealand.

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021 besides analyzing the current market scenario.

What will be the size of the Sciatica Treatment Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation by End-user, Product, and Geography Analysis

Technavio has segmented the market into End-user, Product, and Geography

• The end-user is classified into hospitals, clinics, and others
• The product is classified into non-surgical treatment and surgical treatment
• The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)

End-user Analysis

Hospital

The market share growth by the hospital segment will be significant during the forecast period. Hospitals are a significant segment of the global market since they are the main locations where the treatments are carried out, and patients receive medical attention. In sciatica, the two most common surgical procedures are microdiscectomy and laminectomy.

Get a glance at the market contribution of various segments View a PDF Sample

The hospital segment was valued at USD 7.09 billion in 2017. Microdiscectomy involves correcting a herniated disc in the lower back or bone spurs to relieve pressure on the sciatic nerve. The global market is being driven by an increase in the number of cases of sciatica across the globe. The surgical or non-surgical treatments owing to high cases of sciatica are driving the hospital visits of patients driving the global market during the forecast period.

Product Analysis

Non-surgical treatment

Nonsurgical treatments for sciatica include epidural corticosteroid injections, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, narcotics, tricyclic antidepressants, anti-seizure medications, and physical therapies. The availability of off-label epidural corticosteroid injections for the treatment of sciatica has contributed to the growth of this segment. The growth of the nonsurgical treatment segment is likely to be driven by the expected approvals of drugs for the treatment of sciatica. The expected approvals of drugs for the treatment of sciatica are likely to generate revenue and eventually augment the growth of the nonsurgical treatment segment, fueling the global market during the forecast period.

Surgical treatment 

Surgery is usually recommended to adjust the herniated disc or remove a misplaced vertebra in some patients with severe sciatica. Microdiscectomy and laminectomy are the two common surgical procedures for sciatica. To relieve pressure on sciatic nerves, microdiscectomy is performed to adjust a lumbar herniated disc or bone spur. Laminectomy is the process of removal of a portion of the vertebra, called the lamina, to relieve pressure on the sciatic nerve. For patients who do not respond to conventional treatment, these two surgical options are available. The growth of this segment is attributed to the increasing awareness about the surgical treatment for sciatica.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. In 2022, North America dominated the global market, primarily due to the rising awareness about the condition and strategic alliances among vendors in this region. The awareness about sciatica is increasing among people in countries such as the US and Canada. The growing popularity of cost-effective generic medicinal products is limiting market growth in North America. Cyclobenzaprine is part of a group of medications referred to as cyclical antidepressants. However, the growing geriatric population and high rate of working population across North America are expected to fuel the growth of the regional market at a significant rate during the forecast period.

Buy Now Full Report and Discover More

Key Sciatica Treatment Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Apotex Inc.- The company offers sciatica treatment products such as Etodolac Capsules USP.

• Amneal Pharmaceuticals Inc.
• Aurobindo Pharma Ltd.
• Bayer AG
• Dr Reddys Laboratories Ltd.
• Elam Pharma Pvt. Ltd.
• Fresenius SE and Co.
• KGaA
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals Plc
• Johnson and Johnson
• KOLON LIFE SCIENCE
• Lupin Ltd.
• Novartis AG
• Omega Laser Systems Ltd.
• Ozone Pharmaceuticals Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is witnessing significant growth driven by several key factors and emerging trends. Firstly, there's a growing incidence of sciatic nerve-related conditions globally, attributed to various factors such as age-related changes, obesity, occupations involving prolonged sitting, diabetes, osteoarthritis, spondylolisthesis, and spinal stenosis. As these conditions become more prevalent, the demand for effective treatment options to alleviate symptoms like lower back pain, stiffness, and burning sensations continues to rise. Consequently, healthcare providers and pharmaceutical companies are increasingly investing in research and development to develop innovative medications and therapies that offer both relief and improved efficacy and safety profiles. This trend towards investment in advanced treatments reflects a commitment to meeting the rising demand for sciatica treatment while ensuring patient satisfaction and well-being. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

The market is experiencing growth due to the escalating prevalence of risk factors associated with the condition. Factors such as age-related changes in the spine, diseases like lumbar spinal stenosis and osteoarthritis, and lifestyle factors including obesity and prolonged sitting contribute to the rising incidence of sciatica. As the aging population expands and lifestyles become increasingly sedentary, the occurrence of conditions leading to sciatica is on the rise. This surge in patients with predisposing conditions is expected to fuel the demand for sciatica treatment options. Consequently, healthcare investments and advancements in medication for providing relief from sciatic nerve pain are anticipated to witness an uptick, driven by the imperative need to address the efficacy and safety concerns associated with managing this debilitating symptomatology.

Significant Market Trends

The development of clonidine micropellet epidural injections is a key trend in the market. In the treatment of sciatica at present, there are no approved antiepileptic steroids. Although off-label compounded steroid preparations may reduce inflammations to a certain extent, the side effects associated with them are decreasing their preference. Hence, some pharmaceutical companies began to develop micropellet technology injectables that use a nonsteroidal epidural solution for the treatment of patients with sciatica who do not respond to existing treatments.

Mreover, in order to reduce pain and inflammation, the micropellet technology epidural injection can give local delivery of medication into the nerves in question. The safety and efficacy of clonidine are expected to be better with this novel technology than that of the off-label steroidal epidural injections in the treatment of pain. Therefore, the medications developed with micropellet technology are expected to enter the market during the forecast period and add significant value to its growth.

Major Market Challenges

The lack of approved treatments is a major challenge in the market. Sciatica is a condition in which pain radiates along the path of the sciatic nerve.  Epidural corticosteroids, physiotherapy, and bracing are the most recommended treatments for symptoms. Most of the patients benefit from this combination of treatment methods.

However, there is no approved treatment for sciatica. Sometimes, surgery is recommended for the treatment of persistent pain. To reduce pain caused by pressure on the sciatic nerve, surgery is used to remove a portion of the spinal vertebra known as the luma. Therefore, the lack of approved treatments is expected to hamper the growth of the global market during the forecast period.

Buy Now Full Report and Discover More

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• End-user Outlook
  • Hospital
  • Clinics
  • Others

• Product Outlook
  • Non-surgical treatment
  • Surgical treatment

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • ROW
    • Argentina
    • Australia
    • Rest of The World

Market Analyst Overview

The market is influenced by various factors related to the condition's causes, symptoms, and treatment methods. Sciatica, characterized by pain radiating along the sciatic nerve pathway, primarily affects the buttocks, legs, and lower spine. Risk factors such as obesity, prolonged sitting, diabetes, and degenerative disk disease contribute to its prevalence. As chronic back pain becomes a global concern, demand for effective treatments rises. Pharmaceutical manufacturing facilities, hospital pharmacies, and drug retail stores play crucial roles in providing analgesics, NSAIDs, anticonvulsants, and other medications for pain management. Clinical trial programs and innovations in pain relief techniques drive advancements in sciatica treatment. However, challenges such as complications from sciatic surgery, internal bleeding, infections, and the need for specialized physical therapy and chiropractic devices underscore the complexity of managing this condition, requiring comprehensive approaches encompassing medication, therapy, and home care to alleviate symptoms and improve patient's quality of life.

The market encompasses a wide array of interventions to address acute and chronic sciatica, which affects the lower back, buttocks, and legs due to irritation or compression of the sciatic nerve. Treatment options range from non-steroidal anti-inflammatory drugs (NSAIDs) and anesthetics to specialized physical therapy and medication categories tailored to alleviate symptoms such as stiffness and burning sensations. With the World Health Organization highlighting the rising incidence of lower back pain globally, investments in production facilities and supply chain infrastructure are crucial for ensuring access to effective treatments. Statistics on injury and tumors underscore the importance of specialty care and targeted interventions in managing sciatica for improved patient outcomes.

Sciatica Treatment Market Scope
Report Coverage	Details
Page number	159
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 4.83%
Market growth 2023-2027	USD 3.09 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	4.13
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 37%
Key countries	US, Canada, UK, Germany, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Bayer AG, Dr Reddys Laboratories Ltd., Elam Pharma Pvt. Ltd., Fresenius SE and Co. KGaA, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Johnson and Johnson, KOLON LIFE SCIENCE, Lupin Ltd., Novartis AG, Omega Laser Systems Ltd., Ozone Pharmaceuticals Ltd., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch